Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
In a paper published online in the Journal of Alzheimer's Disease (https://doi.org/10.3233/JAD-191173), TauRx reported that the drug it is developing for the treatment of Alzheimer's disease...
ABERDEEN, Scotland and SINGAPORE, Nov. 27, 2017 /CNW/ - TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in...
Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's...
ABERDEEN, Scotland and SINGAPORE, Oct. 8, 2015 /CNW/ - TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, today announced the...
Over 300 patients now enrolled worldwide in clinical trials for a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer's SINGAPORE and ABERDEEN, Scotland,...
The time for Tau is now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's MONTE CARLO, Monaco, Oct. 30, ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.